Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14791 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Guangcai Shao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Shengjing Hospital, China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Glioblastoma, Immunotherapy, Brain Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Liaoning Youth Science Project.
Abstract (Originalsprache)
Introduction
Glioblastoma (GBM) remains a challenging brain tumor to treat, with limited response to PD‐1 immunotherapy due to tumor‐associated macrophages (TAMs), specifically the M2 phenotype. This study explores the potential of MS4A4A (membrane spanning four domains, subfamily A, member 4A) inhibition in driving M2 macrophage polarization toward the M1 phenotype via the ferroptosis pathway to enhance the effectiveness of immunotherapy in GBM.
Methods
Single‐cell RNA sequencing and spatial transcriptomic analyses were employed to characterize M2 macrophages and MS4A4A expression in GBM. In vitro studies utilizing TAM cultures, flow cytometry, and western blot validations were conducted to assess the impact of MS4A4A on the tumor immune microenvironment and M2 macrophage polarization. In vivo models, including subcutaneous and orthotopic transplantation in mice, were utilized to evaluate the effects of MS4A4A knockout and combined immune checkpoint blockade (ICB) therapy on tumor growth and response to PD‐1 immunotherapy.
Results
Distinct subsets of GBM‐associated macrophages were identified, with spatial distribution in tumor tissue elucidated. In vivo experiments demonstrated that inhibiting MS4A4A and combining ICB therapy effectively inhibited tumor growth, reshaped the tumor immune microenvironment by reducing M2 TAM infiltration and enhancing CD8 + T‐cell infiltration, ultimately leading to complete tumor eradication.
Conclusion
MS4A4A inhibition shows promise in converting M2 macrophages to M1 phenotype via ferroptosis, decreasing M2‐TAM infiltration, and enhancing GBM response to PD‐1 immunotherapy. These findings offer a novel approach to developing more effective immunotherapeutic strategies for GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Shengjing Hospital, China Medical University, Shenyang, China.
- Department of Neurosurgery, Anshan Central Hospital, Anshan, China.
- Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital, China Medical University, Shenyang, China.
- Department of Anesthesiology, The First Hospital of China Medical University, Shenyang, China.
- Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.
- Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, China.
ORCID-Profile: Xiang Li
Förderung
- Liaoning Youth Science Project
Zitieren
APA
Shao, G., Cui, X., Wang, Y., Luo, S., Li, C., Jiang, Y., Cai, D., Li, N., & Li, X. (2024). Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14791
Vancouver
Shao G, Cui X, Wang Y, Luo S, Li C, Jiang Y, et al. Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14791
BibTeX
@article{Shao2024,
author = {Shao, Guangcai and Cui, Xiangguo and Wang, Yiliang and Luo, Shuyan and Li, Chuanyu and Jiang, Yu and Cai, Dasheng and Li, Nu and Li, Xiang},
title = {Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14791}
}
EUVIMED